EUVIMEDEUVIMED entdecken
Open Access

A novel TM4SF4-targeting therapeutic antibody candidate with antitumor activity by blocking IGF1R and CD44 signaling and downregulating PD-L1 and B7-H4

Rae-Kwon Kim, Chang-Kyu Heo, Mun Ju Choi, Yeon-Jee Kahm, Min Kyu Kim, Minyong Lee, Ji Yoon Lee, Hwangseo Park, Uhee Jung, Byung-Chul Shin, Bum-Jin Kim, Sung-Chul Kim und 3 weitere

Theranostics · 2026

DOI: 10.7150/thno.113347 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Theranostics, 2026. Verfasst von Rae-Kwon Kim und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Biology, Environmental Radiation Research Group, Korea Atomic Energy Research Institute (KAERI), Daejeon 34057, Republic of K…. Hauptthemen laut MEDLINE: Receptor, IGF Type 1, B7-H1 Antigen, Hyaluronan Receptors, V-Set Domain-Containing T-Cell Activation Inhibitor 1. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, IGF Type 1B7-H1 AntigenHyaluronan ReceptorsV-Set Domain-Containing T-Cell Activation Inhibitor 1Carcinoma, Non-Small-Cell LungAntibodies, MonoclonalLung NeoplasmsHumansAnimalsMiceSignal TransductionCell Line, TumorXenograft Model Antitumor AssaysEpithelial-Mesenchymal TransitionDown-RegulationFemaleMice, Inbred BALB C

Stichwörter der Autor:innen

EMT-associated stemnessTM4SF4humanized antibody (Hz2B7-1.2)monoclonal antibody (2B7)signaling blocking

Substanzen

Receptor, IGF Type 1B7-H1 AntigenIGF1R protein, humanHyaluronan ReceptorsV-Set Domain-Containing T-Cell Activation Inhibitor 1Antibodies, MonoclonalCD274 protein, humanVTCN1 protein, humanCD44 protein, human

Autor:innen und Institutionen

  • Department of Radiation Biology, Environmental Radiation Research Group, Korea Atomic Energy Research Institute (KAERI), Daejeon 34057, Republic of Korea.
  • Department of Biotechnology, Yong In University, 134, Yongindaehak-ro, Cheoin-gu, Yongin-si, Gyeonggi-do, 17092, Republic of Korea.
  • Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Republic of Korea.
  • Department of Integrative Bioscience and Biotechnology, Institute of Bioscience, Institute of anticancer medicine development, Sejong University, Seoul 05006, Republic of Korea.
  • Department of Radiation Life Science, Korea University of Science and Technology (UST), Daejeon 34113, Republic of Korea.
  • Algok Bio Inc. 320 120th Ave. NE #208 Bellevue, WA 98005, USA.

Zitieren

APA

Kim, R. K., Heo, C. K., Choi, M. J., Kahm, Y. J., Kim, M. K., Lee, M., Lee, J. Y., Park, H., Jung, U., Shin, B. C., Kim, B. J., Kim, S. C., Cho, E. W., Ryu, C. J., & Kim, I. G. (2026). A novel TM4SF4-targeting therapeutic antibody candidate with antitumor activity by blocking IGF1R and CD44 signaling and downregulating PD-L1 and B7-H4. Theranostics. https://doi.org/10.7150/thno.113347

Vancouver

Kim RK, Heo CK, Choi MJ, Kahm YJ, Kim MK, Lee M, et al. A novel TM4SF4-targeting therapeutic antibody candidate with antitumor activity by blocking IGF1R and CD44 signaling and downregulating PD-L1 and B7-H4. Theranostics. 2026. doi:10.7150/thno.113347

BibTeX
@article{Kim2026,
  author = {Kim, Rae-Kwon and Heo, Chang-Kyu and Choi, Mun Ju and Kahm, Yeon-Jee and Kim, Min Kyu and Lee, Minyong and Lee, Ji Yoon and Park, Hwangseo and Jung, Uhee and Shin, Byung-Chul and Kim, Bum-Jin and Kim, Sung-Chul and Cho, Eun-Wie and Ryu, Chun Jeih and Kim, In-Gyu},
  title = {A novel TM4SF4-targeting therapeutic antibody candidate with antitumor activity by blocking IGF1R and CD44 signaling and downregulating PD-L1 and B7-H4},
  journal = {Theranostics},
  year = {2026},
  doi = {10.7150/thno.113347}
}
Kostenlos starten →